Development of an antibiotic marker-free platform for heterologous protein production in Streptomyces
© The Author(s) 2017
Received: 6 July 2017
Accepted: 20 September 2017
Published: 26 September 2017
The industrial use of enzymes produced by microorganisms is continuously growing due to the need for sustainable solutions. Nevertheless, many of the plasmids used for recombinant production of proteins in bacteria are based on the use of antibiotic resistance genes as selection markers. The safety concerns and legal requirements surrounding the increased use of antibiotic resistance genes have made the development of new antibiotic-free approaches essential.
In this work, a system completely free of antibiotic resistance genes and useful for the production of high yields of proteins in Streptomyces is described. This system is based on the separation of the two components of the yefM/yoeBsl (antitoxin/toxin) operon; the toxin (yoeBsl) gene, responsible for host death, is integrated into the genome and the antitoxin gene (yefMsl), which inactivates the toxin, is located in the expression plasmid. To develop this system, the toxin gene was integrated into the genome of a strain lacking the complete operon, and the antibiotic resistance gene integrated along with the toxin was eliminated by Cre recombinase to generate a final host strain free of any antibiotic resistance marker. In the same way, the antibiotic resistance gene from the final expression plasmid was removed by Dre recombinase. The usefulness of this system was analysed by checking the production of two hydrolases from different Streptomyces. Production of both proteins, with potential industrial use, was high and stable over time after strain storage and after serial subcultures. These results support the robustness and stability of the positive selection system developed.
The use of living organisms to produce commercially important value-added biomolecules is of great importance for the different industrial sectors of society such as agriculture, food, energy and pharmaceutical. Recently, Zhang et al. classified the use of organisms, called biomanufacturing, into four historical revolutions. Heterologous protein production, also called biologics , corresponds to what is known as biomanufacturing 3.0. This type of technology began in the 1980s with the production of large-size proteins like erythropoietin, insulin, among others, from genetically modified microorganisms  thanks to the development of recombinant DNA and advanced cell culture techniques.
Many of the proteins produced by this DNA recombinant technology are hydrolytic enzymes like amylases, cellulases, hemicellulases, lipases and proteases, which are important products for many different types of industries such as food and beverages, textile, detergent, pharmaceuticals , animal feed , biofuels and fine-chemical industries, among others. Presently, approximately 90% of industrial enzymes are recombinant versions produced in bacteria and fungi , and their use is expected to increase due to a growing need for sustainable solutions. Moreover, the discovery of new enzymes to add to the currently available toolbox and the development of optimized strategies for the production of these hydrolytic enzymes is a central goal of many industrial sectors .
There is a wide spectrum of hosts used as expression systems for the production of recombinant proteins that include bacteria, yeast, filamentous fungi, insect and mammalian cells and whole transgenic plants and animals . Although the use of each host has different advantages and disadvantages, their main objective is process optimisation . The most commonly used host to produce recombinant proteins is E. coli owing to its easy and rapid growth. However, the use of E. coli does present several drawbacks which can be overcome by the use of other types of host. Gram-positive hosts, such as Streptomyces, are an excellent alternative due to high secretion efficiency, which makes their use feasible for the direct release of proteins of interest into the culture medium. This in turn facilitates downstream procedures, such as extraction and purification, and consequently decreases the costs associated with the production of recombinant proteins. In addition, some Streptomyces strains have a relatively low level of endogenous extracellular proteolytic activity in comparison with other hosts [8, 9]. Also, Streptomyces has proved useful to produce high levels of different proteins [8–12].
The use of enzymes produced by microorganisms as biocatalysts in industry can be considered “green chemistry” because no toxic waste is generated . Nevertheless, many of the plasmids used for recombinant production of enzymes are based on the use of antibiotic resistance genes as selection markers. Due to the intensifying problem of the appearance of antibiotic resistant strains [13–15] and more legal requirements, it is important to avoid the use of these antibiotics as much as possible in the industrial process. As regards different antibiotic-free approaches have been developed, which include the complementation of auxotrophic bacterial strains, toxin-antitoxin-based systems, operator-repressor titration, RNA-based selection markers and the overexpression of essential genes. These alternative selection systems are summarized in Vandermeulen et al. .
Toxin-antitoxin systems (TAs) are ubiquitous in plasmids and genomes of bacteria and archaea, and are small genetic modules composed of a biologically active protein molecule (toxin) and the corresponding inhibitor (antitoxin). Many functions have been assigned to TAs like DNA stabilization, stress response, persistence and protection against mobile genetic elements [17–20]. The efficiency of these TAs depends on the different stability of both components, where toxins are highly resistant to proteases and antitoxins are more labile and readily degraded by proteases.
In view of this, our group developed a separate component stabilization (SCS) system for Streptomyces lividans based on the yefM/yoeBsl toxin-antitoxin operon . In this system the toxin (yoeBsl) gene, responsible for host death, is integrated into the genome, and the antitoxin (yefMsl) gene which inactivates the toxin is located in the expression plasmid . To develop this system, the toxin (yoeBsl) gene was integrated into the genome of a strain lacking the complete operon, and with the antitoxin (yefMsl) gene carried by a thermosensitive plasmid [strain: S. lividans ∆TA (pGM160-YefMslts)] . This strain was the starting point for the improvement of the Streptomyces SCS expression system, as described in the Results section. After toxin integration, the expression plasmids with the gene(s) of interest and the antitoxin are introduced into the host strain [S. lividans ∆TA-pKC796-Tox (pGM160-YefMslts)] in place of the thermosensitive plasmid, and ultimately used for heterologous protein production. Thus, the antitoxin counteracts the effect of the toxin when the expression plasmid is present in the cell. By contrast, when the plasmid is lost the toxin causes cell death, ensuring that only the plasmid-containing cells persist . Using this system, stable and high proteins yields, without the addition of antibiotics into the production process, was achieved . This SCS strategy has also been shown to be effective in E. coli [23–26].
Additionally, it must be noted that although this SCS system does not require the addition of antibiotics to maintain the stable production of enzymes of interest, the antibiotic markers are still present in the host strain and in the expression plasmids used. These antibiotic resistance genes comprise a potential risk for antibiotic resistance transmission by horizontal gene transfer [27–29].
With this antibiotic marker-free system, the production of two proteins, the α-amylase Amy from S. griseus IMRU3570  and the xylanase Xys1 from S. halstedii JM8 , was high and stable over time, validating the efficiency of this new platform for heterologous production of proteins in S. lividans. To our knowledge this is the first complete antibiotic marker-free system developed for Streptomyces. Thus, the total absence of antibiotic resistance genes presents an interesting potential use of this system in industry.
Results and discussion
Construction of an antibiotic marker-free host strain
Streptomyces lividans ΔTA (pGM160-YefMslts) strain , which harbours the temperature sensitive plasmid pGM160-YefMslts with the antitoxin gene (yefMsl) , was transformed with pTES-Tox generating the strain S. lividans ∆TA-pTES-Tox (pGM160-YefMslts) (step 1 in Fig. 1). Then, this strain was transformed with the plasmid pALCrets  encoding the Cre recombinase yielding S. lividans ∆TA-pTES-Tox (pGM160-YefMslts, pALCrets) strain (step 2 in Fig. 1). Afterwards, the induction of this Cre recombinase allowed the plasmid backbone between the two loxP sites to be deleted, leaving only the toxin gene integrated in the genome (Fig. 2b). Successful elimination of the apramycin resistance gene was checked by PCR (Fig. 2c). The strain obtained after the elimination of apramycin gene was designated S. lividans ∆TA-Tox (pGM160-YefMslts, pALCrets) (step 3 in Fig. 1) and was used as the final antibiotic marker-free host to produce heterologous proteins in S. lividans.
Effectiveness of the antibiotic marker-free host strain to produce high levels of protein
The usefulness of this new strain S. lividans ∆TA-Tox (pGM160-YefMslts, pALCrets), without apramycin resistance in its genome, was analysed by checking the production of two proteins: the Amy α-amylase from S. griseus IMRU3570  and the Xys1 xylanase from S. halstedii JM8 . S. lividans wt and S. lividans ∆TA strains were used as controls.
Streptomyces lividans ∆TA-Tox (pGM160-YefMslts, pALCrets) and the control strains (S. lividans wt and S. lividans ∆TA) were transformed with pNRoxAnti-Amy or pNRoxAnti-Xyl (step 4 in Fig. 1). After removal of the temperature sensitive plasmids (pGM160-YefMslts and pALCrets) by incubation at 37 °C, the transformants were cultured at 28 °C in liquid YES medium without antibiotic and supplemented with 3% xylose to induce both promoters. The production of amylase or xylanase was analysed by SDS-PAGE of the supernatants collected after 6 days of culture (Fig. 3b, d).
A high production of amylase or xylanase was observed with the S. lividans ∆TA-Tox strain; however, no amylase and xylanase production was observed in the control strains (S. lividans wt and S. lividans ∆TA) (Fig. 3b, d). These results indicate that the toxin gene in the genome of the S. lividans ∆TA-Tox strain was exerting a positive selection for the maintenance of the expression plasmids containing the antitoxin, since the loss of the latter results in cell death. In contrast, in absence of antibiotic selection pressure, the expression plasmids (pNRoxAnti-Amy or pNRoxAnti-Xyl) present in the control strains (S. lividans wt and S. lividans ∆TA) were lost and consequently no protein production was observed (Fig. 3b, d).
Therefore, the new strain (S. lividans ∆TA-Tox) without apramycin resistance allowed positive plasmid selection in the same way as the previously reported (S. lividans ∆TA-pKC796-Tox)  but without the potential problems associated with the remaining presence of an antibiotic resistance gene in the host strain.
Elimination of the antibiotic marker gene in the expression plasmid and analysis of protein production
Nevertheless, it is still necessary to eliminate the neomycin resistance gene present in the expression plasmids used (pNRoxAnti-Amy or pNRoxAnti-Xyl) in order to generate a completely antibiotic marker-free system. This antibiotic resistance gene was necessary to make the constructions in E. coli but was subsequently eliminated in Streptomyces. To facilitate the deletion of the antibiotic marker gene, the target sites for Dre recombinase (rox)  were introduced flanking the neomycin resistance gene as mentioned before.
In order to check the effective deletion of the neomycin resistance gene, after the elimination of the pALDrets plasmid (step 6 in Fig. 1), the plasmids pRoxAnti-Amy and pRoxAnti-Xyl were recovered from the corresponding S. lividans ∆TA-Tox strains and the elimination of the neomycin gene was confirmed by PCR and by restriction analysis (Fig. 4b, c).
The amount of protein produced after the elimination of the marker gene was analysed and compared to that produced with the parental plasmids harbouring the neomycin resistance gene. Transformants of S. lividans ∆TA-Tox (pRoxAnti-Amy) or ∆TA-Tox (pRoxAnti-Xyl) and transformants of S. lividans ∆TA-Tox (pNRoxAnti-Amy) or ∆TA-Tox (pNRoxAnti-Xyl) were cultured for 6 days at 28 °C in liquid YES medium without antibiotic, and supplemented with 3% xylose. The production of amylase or xylanase was analysed by SDS-PAGE using the collected supernatants (Fig. 4d, e). The amount of amylase and xylanase produced after the elimination of the neomycin resistance gene was similar to that obtained with the neomycin resistant plasmids (Fig. 4d, e).
At the end of this process, a new expression platform for Streptomyces completely free of antibiotic resistance genes was developed and suitable to produce proteins at industrial level.
A robust system for producing proteins at the industrial level must have a high protein yield and also be able to maintain stable production. Stability of the developed antibiotic marker-free platform was analysed under different conditions such as long-term culturing, after the strains were stored as frozen mycelia or as frozen spores and after serial subcultures.
Finally, plasmid stability was assessed after three serial 100-fold dilutions (P1, P2 and P3) of cultures in fresh YES medium every 2 days. Using the same procedure as mentioned above, the amount of enzyme in the supernatant of each subculture was analyzed by SDS-PAGE after 6 days (Fig. 6e, g). Also enzymatic activity was measured (Fig. 6f, h) and compared with the activity obtained in the first culture of the series. It should be noted that there was even an enhanced production of both amylase and xylanase throughout the different passages, and as consequence an increase in the enzymatic activity of the supernatants.
All of these results support the robustness and stability of this improved selection system.
In this work, a system that is completely free of antibiotic resistance genes and useful for the production of high yields of proteins in Streptomyces without the use of antibiotics as selective agents is reported.
This system is an improved version of the system previously described by our group, and is based on the separation of the two components of the yefM/yoeBsl (toxin/antitoxin) operon. The absence of antibiotic resistance genes brings additional value to this expression system and makes using Streptomyces as a host a powerful tool for the production of proteins that can be used within different industrial sectors.
Bacterial strains and growth conditions
The E. coli DH5α strain  was used for the cloning and isolation of plasmids. It was grown in Luria–Bertani (LB) liquid broth or on LB agar. All manipulations in E. coli were done following standard procedures [38, 39].
Streptomyces lividans 1326 and derivatives were grown on solid R2YE medium for transformation, on MSA medium for sporulation , and in liquid YES medium (1% yeast extract, 10.3% sucrose, 5 mM MgCl2) supplemented with 0.5% glucose and 0.5% glycine for collecting cells to make protoplasts, and YES medium supplemented with 3% xylose for protein expression. Liquid cultures were carried out in baffled flasks at 28 °C and 200 rpm. All manipulations in Streptomyces were done as indicated by Kieser .
Apramycin gene deletion in the host strain
Forward (Fd) for yefMsl amplification. NdeI sequence is underlined
Reverse (Rev) for yefMsl amplification. HindIII sequence is underlined
Fd for yoeBsl amplification. NdeI sequence is underlined
Rev for yoeBsl amplification. XhoI sequence is underlined
Fd for aac(3′)IV (apramycin resistance gene) amplification
Rev for aac(3′)IV (apramycin resistance gene) amplification
Fd for aph(3′) (neomycin resistance gene) amplification
Rev for aph(3′) (neomycin resistance gene) amplification
Fd for amy amplification. NdeI sequence is underlined
Rev for amy amplification. XhoI sequence is underlined
Fd for xysA amplification
Rev for xysA amplification
Neomycin gene deletion in the expression plasmids
Transformation of the host strain with the expression plasmids and colony selection was done as described in Sevillano et al. . Protoplasts of S. lividans ∆TA-Tox (pNRoxAnti-Amy) or ∆TA-Tox (pNRoxAnti-Xyl) were transformed with pALDrets  and selected with 100 μg/mL hygromycin. Single colonies were reinoculated in patches on R2YE plates for 3 days and then streaked out on R2YE plates to obtain single colonies. The single colonies were picked and streaked in parallel on R2YE agar, R2YE agar with 15 μg/mL neomycin and R2YE agar with 100 μg/mL hygromycin to check for the loss of neomycin resistance and the loss of the pALDrets plasmid. Elimination of the neomycin resistance gene in the plasmid was checked by PCR using primers LS-124 and LS-125 (Table 1) and by restriction analysis.
E. coli/Streptomyces shuttle vector. Thiostrepton and gentamicin resistance
pGM160 derivative. The xysA promoter from S. halstedii controls yefMsl expression
E. coli/Streptomyces shuttle vector. Neomycin resistance. High-copy number
pN702GEM3 derivative. The xysA promoter from S. halstedii controls toxin expression
E. coli/Streptomyces shuttle vector. Apramycin resistance. Integrative plasmid. attP flanked by loxP sites
pTES derivative. The xysA promoter from S. halstedii controls toxin expression
pBluescript SK derivative. Ampicillin resistance. The xysA promoter from S. halstedii controls xylanase expression
pXHis1 derivative. The xysA promoter from S. halstedii controls antitoxin expression
E. coli/Streptomyces shuttle vector. Apramycin resistance. Integrative plasmid. attP flanked by rox sites
pTOS derivative. The neomycin resistance gene is flanked by rox sites
pN702Gem3 derivative. The neomycin resistance gene is flanked by rox sites
pN702Gem3Rox derivative. The xysA promoter from S. halstedii controls antitoxin expression
pN702Gem3 derivative. The pstS promoter from S. lividans controls xylanase expression
pNUF5 derivative. The pstS promoter from S. lividans controls amylase expression
pN702Gem3Rox-Anti-T derivative. The xysA promoter from S. halstedii controls antitoxin expression and the pstS promoter from S. lividans controls xylanase expression
pN702Gem3Rox-Anti-T derivative. The xysA promoter from S. halstedii controls antitoxin expression and the pstS promoter from S. lividans controls amylase expression
pNRoxAnti-Xyl derivative without neomycin resistance gene
pNRoxAnti-Amy derivative without neomycin resistance gene
Plasmid pN702Gem3  was digested with BlpI, blunt ended with DNA polymerase klenow fragment and then digested with NheI. The DNA fragment containing the aph(3′) (neomycin resistance) gene was ligated into pTOS  digested with EcoRV and XbaI to obtain pTOS-Neo, which was used as an intermediate plasmid. To obtain pN702Gem3Rox, pTOS-Neo was digested with BspHI and HincII, and the DNA fragment containing the aph(3′) gene flanked by rox sites was blunt ended and ligated into pN702Gem3 digested with BlpI and NheI and blunt. In this plasmid two rox sites flank the neomycin resistance gene.
yefMsl (antitoxin) was amplified by PCR from S. lividans 1326 genomic DNA using primers LS-005 and LS-007 (Table 1). The resulting fragment was digested with NdeI and HindIII and ligated into plasmid pXHis1,  (Table 2) digested with the same enzymes, to obtain plasmid pXHis1-Anti-T, which was used as an intermediate plasmid. Plasmid pN702Gem3Rox-Anti-T was obtained by digesting pXHis1-Anti-T with BglII, purifying the corresponding yefMsl band and ligating it into pN702Gem3Rox digested with the same enzyme. In this plasmid, the antitoxin gene is regulated by the xysA promoter and lacks the fdt transcriptional terminator at 3′ end.
This plasmid contains the ORF of the xylanase xysA gene from S. halstedii  under the control of the S. lividans pstS promoter, and the ORF coding for the antitoxin (YefMsl) under the control of the xysA promoter. The plasmid originated from the pNUF5 plasmid  which contains the xylanase gene regulated by pstSp; pNUF5 was digested with BspHI and NheI, and the xysA gene band was ligated into pN702Gem3Rox-Anti-T digested with BspHI and XbaI.
This plasmid contains the ORF of the amylase gene from S. griseus  under the control of the S. lividans pstS promoter and the ORF coding for the antitoxin (YefMsl) under the control of the xysA promoter. To construct the plasmid, plasmid pNUF-Amy , which contains the amylase gene regulated by pstSp, was digested with BspHI and NheI and the corresponding band was ligated into pN702Gem3Rox-Anti-T digested with BspHI and XbaI.
All constructions were sequenced on both strands using a Perkin Elmer ABI Prism 377 DNA sequencer. In silico plasmids were obtained with the Gene Construction Kit software (GCK, Textco).
Protein profiles were analysed by denaturing polyacrylamide gel electrophoresis (SDS-PAGE) in a MiniProtean II system (Bio-Rad). Proteins were detected by 0.5% Coomassie brilliant blue R staining and low molecular weight standards from Bio-Rad were used as markers.
Xylanase and amylase activities assays
Xylanase activity was measured with the dinitrosalicylic acid (DNS) method  using xylose as standard. One unit of xylanase activity was defined as the amount of enzyme required to release 1 µmol of reducing sugars in 1 min (expressed as xylose equivalents). All data shown are means of at least three different experiments.
Amylase activity was measured with the method described by Xiao . One unit of amylase activity was defined as the amount of enzyme required to degrade 1 mg of soluble starch in 1 h. All data shown are means of at least three different experiments.
LS designed the experiments, performed the experimental work and wrote the manuscript. MD and RS directed the work and helped to write the manuscript. All authors read and approved the final manuscript.
We are grateful to Dr. A. Luzhetskyy for providing us with plasmids pALCrets, pALDrets, pTES and pTOS and Dr. G. Muth for plasmid pGM160. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI). We would like to thank Ana M. Martínez-Carrasco for her excellent technical support, and we also thank Emma Keck for her help in the English editing.
The authors declare that they have no competing interests.
Availability of data and materials
The plasmids and strains obtained during the current study are available from the corresponding author on reasonable request.
Consent for publication
Ethics approval and consent to participate
Our laboratory is funded by The Spanish Ministry of Economy, Industry and Competitiveness (MINECO) PCIN-2014-067 and BIO2015-66958-R.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Bandyopadhyay AA, Khetan A, Malmberg LH, Zhou W, Hu WS. Advancement in bioprocess technology: parallels between microbial natural products and cell culture biologics. J Ind Microbiol Biotechnol. 2017;44:785–97.View ArticleGoogle Scholar
- Zhang YP, Sun J, Ma Y. Biomanufacturing: history and perspective. J Ind Microbiol Biotechnol. 2017;44:773–84.View ArticleGoogle Scholar
- Sánchez-García L, Martín L, Mangues R, Ferrer-Miralles N, Vázquez E, Villaverde A. Recombinant pharmaceuticals from microbial cells: a 2015 update. Microb Cell Fact. 2016;15:33.View ArticleGoogle Scholar
- Gifre L, Aris A, Bach A, García-Fruitos E. Trends in recombinant protein use in animal production. Microb Cell Fact. 2017;16:40.View ArticleGoogle Scholar
- Adrio JL, Demain AL. Microbial enzymes: tools for biotechnological processes. Biomolecules. 2014;4:117–39.View ArticleGoogle Scholar
- Littlechild JA. Improving the ‘tool box’ for robust industrial enzymes. J Ind Microbiol Biotechnol. 2017;44:711–20.View ArticleGoogle Scholar
- Royle K, Kontoravdi C. A systems biology approach to optimising hosts for industrial protein production. Biotechnol Lett. 2013;35:1961–9.View ArticleGoogle Scholar
- Anne J, Vrancken K, Van Mellaert L, Van Impe J, Bernaerts K. Protein secretion biotechnology in Gram-positive bacteria with special emphasis on Streptomyces lividans. Biochim Biophys Acta. 2014;1843:1750–61.View ArticleGoogle Scholar
- Liu L, Yang H, Shin HD, Li J, Du G, Chen J. Recent advances in recombinant protein expression by Corynebacterium, Brevibacterium, and Streptomyces: from transcription and translation regulation to secretion pathway selection. Appl Microbiol Biotechnol. 2013;97:9597–608.View ArticleGoogle Scholar
- Díaz M, Adham SA, Ramón D, Gil JA, Santamaría RI. Streptomyces lividans and Brevibacterium lactofermentum as heterologous hosts for the production of X22 xylanase from Aspergillus nidulans. Appl Microbiol Biotechnol. 2004;65:401–6.View ArticleGoogle Scholar
- Díaz M, Ferreras E, Moreno R, Yepes A, Berenguer J, Santamaría R. High-level overproduction of Thermus enzymes in Streptomyces lividans. Appl Microbiol Biotechnol. 2008;79:1001–8.View ArticleGoogle Scholar
- Sevillano L, Vijgenboom E, van Wezel GP, Díaz M, Santamaría RI. New approaches to achieve high level enzyme production in Streptomyces lividans. Microb Cell Fact. 2016;15:28.View ArticleGoogle Scholar
- Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M. Achieving global targets for antimicrobial resistance. Science. 2016;353:874–5.View ArticleGoogle Scholar
- Robinson TP, Bu DP, Carrique-Mas J, Fevre EM, Gilbert M, Grace D, Hay SI, Jiwakanon J, Kakkar M, Kariuki S, et al. Antibiotic resistance is the quintessential one health issue. T Roy Soc Trop Med H. 2016;110:377–80.View ArticleGoogle Scholar
- Theuretzbacher U, Ardal C, Harbarth S. Linking sustainable use policies to novel economic incentives to stimulate antibiotic research and development. Infect Dis Rep. 2017;9:6836.View ArticleGoogle Scholar
- Vandermeulen G, Marie C, Scherman D, Preat V. New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials. Mol Ther. 2011;19:1942–9.View ArticleGoogle Scholar
- Goeders N, Van Melderen L. Toxin-antitoxin systems as multilevel interaction systems. Toxins. 2014;6:304–24.View ArticleGoogle Scholar
- Yamaguchi Y, Inouye M. Regulation of growth and death in Escherichia coli by toxin-antitoxin systems. Nat Rev Microbiol. 2011;9:779–90.View ArticleGoogle Scholar
- Yamaguchi Y, Park JH, Inouye M. Toxin-antitoxin systems in bacteria and archaea. Annu Rev Genet. 2011;45:61–79.View ArticleGoogle Scholar
- Yang QE, Walsh TR. Toxin-antitoxin systems and their role in disseminating and maintaining antimicrobial resistance. FEMS Microbiol Rev. 2017;41:343–53.View ArticleGoogle Scholar
- Sevillano L, Díaz M, Yamaguchi Y, Inouye M, Santamaría RI. Identification of the first functional toxin-antitoxin system in Streptomyces. PLoS ONE. 2012;7:e32977.View ArticleGoogle Scholar
- Sevillano L, Díaz M, Santamaría RI. Stable expression plasmids for Streptomyces based on a toxin-antitoxin system. Microb Cell Fact. 2013;12:39.View ArticleGoogle Scholar
- Barroca M, Rodrigues P, Sobral R, Costa MM, Chaves SR, Machado R, Casal M, Collins T. Antibiotic free selection for the high level biosynthesis of a silk-elastin-like protein. Sci Rep. 2016;6:39329.View ArticleGoogle Scholar
- Peubez I, Chaudet N, Mignon C, Hild G, Husson S, Courtois V, De Luca K, Speck D, Sodoyer R. Antibiotic-free selection in E. coli: new considerations for optimal design and improved production. Microb Cell Fact. 2010;9:65.View ArticleGoogle Scholar
- Stieber D, Gabant P, Szpirer C. The art of selective killing: plasmid toxin/antitoxin systems and their technological applications. Biotechniques. 2008;45:344–6.View ArticleGoogle Scholar
- Szpirer CY, Milinkovitch MC. Separate-component-stabilization system for protein and DNA production without the use of antibiotics. Biotechniques. 2005;38:775–81.View ArticleGoogle Scholar
- Crofts TS, Gasparrini AJ, Dantas G. Next-generation approaches to understand and combat the antibiotic resistome. Nat Rev Microbiol. 2017;15:422–34.View ArticleGoogle Scholar
- Hiltunen T, Virta M, Laine AL. Antibiotic resistance in the wild: an eco-evolutionary perspective. Phil Trans R Soc B. 2017;372:20160039.View ArticleGoogle Scholar
- Schroeder M, Brooks BD, Brooks AE. The complex relationship between virulence and antibiotic resistance. Genes. 2017;8:39.View ArticleGoogle Scholar
- Myronovskyi M, Luzhetskyy A. Genome engineering in actinomycetes using site-specific recombinases. Appl Microbiol Biotechnol. 2013;97:4701–12.View ArticleGoogle Scholar
- Fedoryshyn M, Petzke L, Welle E, Bechthold A, Luzhetskyy A. Marker removal from actinomycetes genome using Flp recombinase. Gene. 2008;419:43–7.View ArticleGoogle Scholar
- Fedoryshyn M, Welle E, Bechthold A, Luzhetskyy A. Functional expression of the Cre recombinase in actinomycetes. Appl Microbiol Biothecnol. 2008;78:1065–70.View ArticleGoogle Scholar
- Herrmann S, Siegl T, Luzhetska M, Petzke L, Jilg C, Welle E, Erb A, Leadlay PF, Bechthold A, Luzhetskyy A. Site-specific recombination strategies for engineering actinomycete genomes. Appl Environ Microb. 2012;78:1804–12.View ArticleGoogle Scholar
- García-González MD, Martin JF, Vigal T, Liras P. Characterizacion, expression in Streptomyces lividans, and processing of the amylase of Streptomyces griseus IMRU 3570: two different amylases are derived from the same gene by an intracellular processing mechanism. J Bacteriol. 1991;173:2451–8.View ArticleGoogle Scholar
- Ruiz-Arribas A, Sánchez P, Calvete JJ, Raida M, Fernández-Abalos JM, Santamaría RI. Analysis of xysA, a gene from Streptomyces halstedii JM8 that encodes a 45-kDa modular xylanase, Xys1. Appl Environ Microb. 1997;63:2983–8.Google Scholar
- Díaz M, Esteban A, Fernández-Ábalos JM, Santamaría RI. The high-affinity phosphate-binding protein PstS is accumulated under high fructose concentrations and mutation of the corresponding gene affects differentiation in Streptomyces lividans. Microbiology. 2005;151:2583–92.View ArticleGoogle Scholar
- Fernández-Ábalos JM, Reviejo V, Díaz M, Rodríguez S, Leal F, Santamaría RI. Posttranslational processing of the xylanase Xys1L from Streptomyces halstedii JM8 is carried out by secreted serine proteases. Microbiology. 2003;149:1623–32.View ArticleGoogle Scholar
- Hanahan D. Studies on transformation of Escherichia coli with plasmids. J Mol Biol. 1983;166:557–80.View ArticleGoogle Scholar
- Sambrook J, Fritsch E, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory; 1989.Google Scholar
- Kieser T, Hopwood DA, Bibb JM, Chater KF, Buttner MJ. Practical streptomyces genetics. Norwich: John Innes Foundation; 2000.Google Scholar
- Adham SA, Honrubia P, Díaz M, Fernández-Ábalos JM, Santamaría RI, Gil JA. Expression of the genes coding for the xylanase Xys1 and the cellulase cel1 from the straw-decomposing Streptomyces halstedii JM8 cloned into the amino-acid producer Brevibacterium lactofermentum ATCC13869. Arch Microbiol. 2001;177:91–7.View ArticleGoogle Scholar
- Biely P, Mislovicova D, Toman R. Soluble chromogenic substrates for the assay of endo-1,4-ß-xylanases and endo-1,4-ß-glucanases. Anal Biochem. 1985;144:142–6.View ArticleGoogle Scholar
- Xiao Z, Storms R, Tsang A. A quantitative starch-iodine method for measuring alpha-amylase and glucoamylase activities. Anal Biochem. 2006;351:146–8.View ArticleGoogle Scholar
- Muth G, NuBbaumer B, Wohlleben W, Püler A. A vector system with temperature-sensitive replication for gene disruption and mutational cloning in Streptomyces. Mol Gen Genet. 1989;219:341–8.View ArticleGoogle Scholar